These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11318200)

  • 1. Adjusted regression trend test for a multicenter clinical trial.
    Quan H; Capizzi T
    Biometrics; 1999 Jun; 55(2):460-2. PubMed ID: 11318200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate.
    Lehmacher W; Wassmer G; Reitmeir P
    Biometrics; 1991 Jun; 47(2):511-21. PubMed ID: 1912258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
    Cranney A; Wells G; Willan A; Griffith L; Zytaruk N; Robinson V; Black D; Adachi J; Shea B; Tugwell P; Guyatt G;
    Endocr Rev; 2002 Aug; 23(4):508-16. PubMed ID: 12202465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [To increase bone density faster and stronger].
    MMW Fortschr Med; 2005 May; 147(18):44-5. PubMed ID: 15934589
    [No Abstract]   [Full Text] [Related]  

  • 5. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [FACT study: benefits of alendronate].
    MMW Fortschr Med; 2005 Jan; 147(1-2):52-3. PubMed ID: 15704574
    [No Abstract]   [Full Text] [Related]  

  • 7. Order-restricted tests for stratified comparisons of binomial proportions.
    Agresti A; Coull BA
    Biometrics; 1996 Sep; 52(3):1103-11. PubMed ID: 8805770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
    Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
    Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
    Cummings SR; Palermo L; Browner W; Marcus R; Wallace R; Pearson J; Blackwell T; Eckert S; Black D
    JAMA; 2000 Mar; 283(10):1318-21. PubMed ID: 10714731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
    Adis International Ltd
    Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of herbal medicine BHH10 in postmenopausal women with osteoporosis: study protocol for a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial.
    Cho Y; Lee S; Kim J; Kang JW; Baek YH; Seo BK; Lee JD
    Trials; 2018 Sep; 19(1):482. PubMed ID: 30201024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A random effects model for multivariate failure time data from multicenter clinical trials.
    Cai J; Sen PK; Zhou H
    Biometrics; 1999 Mar; 55(1):182-9. PubMed ID: 11318153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL; Schneider DL; McClung MR; Miller PD; Schnitzer TJ; Bonin R; Smith ME; DeLucca P; Gormley GJ; Melton ME
    Ann Intern Med; 2002 May; 136(10):742-6. PubMed ID: 12020142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of male osteoporosis: recent advances with alendronate.
    Ringe JD; Orwoll E; Daifotis A; Lombardi A
    Osteoporos Int; 2002 Mar; 13(3):195-9. PubMed ID: 11991437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term experience with alendronate in the treatment of osteoporosis.
    Hochberg MC; Rizzoli R
    Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis.
    del Puente A; Scognamiglio A; Itto E; Ferrara G; Oriente P
    J Rheumatol; 2000 Aug; 27(8):1980-3. PubMed ID: 10955341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis.
    Liu GF; Wang ZQ; Liu L; Zhang BT; Miao YY; Yu SN
    J Cell Biochem; 2018 Jun; 119(6):4469-4481. PubMed ID: 29227547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.